Literature DB >> 21417623

The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia.

Fabian Chen1, Vic Maridakis, Edward A O'Neill, Brian K Hubbard, Alison Strack, Chan Beals, Gary A Herman, Peggy Wong.   

Abstract

BACKGROUND: Lipidomic biomarkers will facilitate the development of novel anti-atherosclerotic therapies.
OBJECTIVE: To evaluate the responses of circulating biomarkers to simvastatin treatment.
METHODS: A randomized, cross-over study in men with mixed dyslipidaemia was used to compare effects of simvastatin 40 mg/day with placebo.
RESULTS: Plasma concentrations of nine fatty acids (FA; of 33 evaluated) were reduced significantly by simvastatin. No changes in the rates of FA synthesis or in hepatic lipase or lipoprotein lipase activities were apparent. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased.
CONCLUSION: We identified lipidomic biomarkers of simvastatin treatment effect that are consistent with statin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase (ClinicalTrials.gov: NCT00935259).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417623     DOI: 10.3109/1354750X.2011.561367

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  6 in total

Review 1.  Lipidomics in the Study of Hypertension in Metabolic Syndrome.

Authors:  Hemant Kulkarni; Manju Mamtani; John Blangero; Joanne E Curran
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

2.  Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.

Authors:  Wu Yin; Ester Carballo-Jane; David G McLaren; Vivienne H Mendoza; Karen Gagen; Neil S Geoghagen; Lesley Ann McNamara; Judith N Gorski; George J Eiermann; Aleksandr Petrov; Michael Wolff; Xinchun Tong; Larissa C Wilsie; Taro E Akiyama; Jing Chen; Anil Thankappan; Jiyan Xue; Xiaoli Ping; Genevieve Andrews; L Alexandra Wickham; Cesaire L Gai; Tu Trinh; Alison A Kulick; Marcie J Donnelly; Gregory O Voronin; Ray Rosa; Anne-Marie Cumiskey; Kavitha Bekkari; Lyndon J Mitnaul; Oscar Puig; Fabian Chen; Richard Raubertas; Peggy H Wong; Barbara C Hansen; Ken S Koblan; Thomas P Roddy; Brian K Hubbard; Alison M Strack
Journal:  J Lipid Res       Date:  2011-10-23       Impact factor: 5.922

Review 3.  Lipidomics in vascular health: current perspectives.

Authors:  Genovefa Kolovou; Vana Kolovou; Sophie Mavrogeni
Journal:  Vasc Health Risk Manag       Date:  2015-06-12

4.  Lipidome and transcriptome profiling of pneumolysin intoxication identifies networks involved in statin-conferred protection of airway epithelial cells.

Authors:  Sarah Statt; Jhen-Wei Ruan; Chih-Ting Huang; Reen Wu; Cheng-Yuan Kao
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

Review 5.  Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.

Authors:  Naomi J Rankin; David Preiss; Paul Welsh; Naveed Sattar
Journal:  Int J Epidemiol       Date:  2016-10-27       Impact factor: 7.196

6.  Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial.

Authors:  Estifanos Baye; Jozef Ukropec; Maximilian Pj de Courten; Silvia Vallova; Patrik Krumpolec; Timea Kurdiova; Giancarlo Aldini; Barbara Ukropcova; Barbora de Courten
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.